ProQR Therapeutics (PRQR) Competitors

GH Research (NASDAQ:GHRS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk, institutional ownership and community ranking.

Is GHRS or PRQR more profitable?

GH Research has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. GH Research's return on equity of -20.29% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.29%	-19.49%
ProQR Therapeutics	-134.31%	-71.58%	-19.70%

Does the MarketBeat Community favor GHRS or PRQR?

ProQR Therapeutics received 306 more outperform votes than GH Research when rated by MarketBeat users. However, 76.92% of users gave GH Research an outperform vote while only 61.99% of users gave ProQR Therapeutics an outperform vote.

Company	Underperform	Outperform
GH Research	Outperform Votes 30 76.92%	Underperform Votes 9 23.08%
ProQR Therapeutics	Outperform Votes 336 61.99%	Underperform Votes 206 38.01%

Does the media refer more to GHRS or PRQR?

In the previous week, ProQR Therapeutics had 3 more articles in the media than GH Research. MarketBeat recorded 5 mentions for ProQR Therapeutics and 2 mentions for GH Research. ProQR Therapeutics' average media sentiment score of 1.35 beat GH Research's score of 0.94 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate GHRS or PRQR?

GH Research presently has a consensus target price of $30.86, indicating a potential upside of 178.37%. ProQR Therapeutics has a consensus target price of $9.50, indicating a potential upside of 571.38%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
ProQR Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17

Which has higher earnings & valuation, GHRS or PRQR?

ProQR Therapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$35.59M	-$0.75	-14.78
ProQR Therapeutics	$18.91M	7.87	-$30.43M	-$0.34	-4.16

Which has more risk & volatility, GHRS or PRQR?

GH Research has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in GHRS or PRQR?

56.9% of GH Research shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ProQR Therapeutics beats GH Research on 10 of the 18 factors compared between the two stocks.